MedPath

A randomized controlled trial comparing PCAB and PPI therapy for Los Angeles classification Grade C/D reflux esophagitis patient

Not Applicable
Recruiting
Conditions
Reflux esophagitis
Registration Number
JPRN-UMIN000031633
Lead Sponsor
Yokohama City University (Basic research expenditures)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
160
Inclusion Criteria

Not provided

Exclusion Criteria

(1)A patient with history of gastrectomy which may cause regurgitation of bile acid or pancreatic juice. (2)A patient who use PPI or H2RA already. (3)A patient with pregnancy. (4)A patient with lactation. (5)Past history of allergy for the drug used in this study. (6)Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. (7)A patient who is disqualified for the study by physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Endoscopic cure rate :a rate becoming Las Angeles classification grade M or N.
Secondary Outcome Measures
NameTimeMethod
Subjective symptoms disappearance rate :Using questionnaire for GERD symptom: Frequency Scale for the Symptoms of GERD (FSSG, F-scale), the rate is defined as (pre F-scale score - post F-scale score)/(pre F-scale score)*100. F-scale of pre and post 4 weeks and 8 weeks is used.
© Copyright 2025. All Rights Reserved by MedPath